Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF). Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain. Unsurprisingly, investors reacted positively to the latest regulatory victory, with Vertex's shares jumping on Friday. Is this biotech stock a no-brainer buy now after its huge FDA approval?Vertex CEO Reshma Kewalramani described the FDA approval of Journavx as "a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year." Is that just hype from a corporate executive? I don't think so.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool